Safety and efficacy of switching from branded to generic imatinib in chronic phase chronic myeloid leukemia patients treated in Italy.

MLA

Bonifacio, Massimiliano, et al. “Safety and Efficacy of Switching from Branded to Generic Imatinib in Chronic Phase Chronic Myeloid Leukemia Patients Treated in Italy.” Leukemia Research, vol. 74, Nov. 2018, pp. 75–79. EBSCOhost, https://doi.org/10.1016/j.leukres.2018.09.018.

APA

Bonifacio, M., Scaffidi, L., Binotto, G., Miggiano, M. C., Danini, M., Minotto, C., Griguolo, D., Marin, L., Frison, L., D’Amore, F., Basso, M., Sartori, R., Tinelli, M., Stulle, M., Fortuna, S., Bonalumi, A., Bertoldero, G., De Biasi, E., Ruggeri, M., & Semenzato, G. (2018). Safety and efficacy of switching from branded to generic imatinib in chronic phase chronic myeloid leukemia patients treated in Italy. Leukemia Research, 74, 75–79. https://doi.org/10.1016/j.leukres.2018.09.018

Chicago

Bonifacio, Massimiliano, Luigi Scaffidi, Gianni Binotto, Maria Cristina Miggiano, Marco Danini, Claudia Minotto, Davide Griguolo, et al. 2018. “Safety and Efficacy of Switching from Branded to Generic Imatinib in Chronic Phase Chronic Myeloid Leukemia Patients Treated in Italy.” Leukemia Research 74 (November): 75–79. doi:10.1016/j.leukres.2018.09.018.